Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04785534 · ClinicalTrials.gov registry record · NA
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
A NA study of Liver and Intrahepatic Bile Duct Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT04785534: Active NA study of Liver and Intrahepatic Bile Duct Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT04785534 is a NA study of Liver and Intrahepatic Bile Duct Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,000 participants, above the 32-participant average among 3 other Liver and Intrahepatic Bile Duct Carcinoma trials with a reported enrollment target (3025% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04785534, a NA study of Liver and Intrahepatic Bile Duct Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.
Primary Outcome
The presence of at least one risk factor for hepatitis B virus (HBV) on the screening questionnaire will indicate a positive (versus negative) screening for HBV infection.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Survey Administration
- OTHER Clinical Evaluation
- PROCEDURE Liver Ultrasonographic Elastography
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What the registry record for NCT04785534 still lists
NCT04785534 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 32-participant average among 3 other Liver and Intrahepatic Bile Duct Carcinoma trials with a reported enrollment target (3025% higher).
The record links to 1 condition, with Liver and Intrahepatic Bile Duct Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT04785534 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04785534 about?
NCT04785534 is a clinical study titled "Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis". This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Informati...
What is the current status of trial NCT04785534?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2020-12-22. Estimated completion is 2026-08-31.
What conditions does trial NCT04785534 study?
This clinical trial studies the following conditions: Liver and Intrahepatic Bile Duct Carcinoma.
What interventions are being tested in trial NCT04785534?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Survey Administration (OTHER), Clinical Evaluation (OTHER), Liver Ultrasonographic Elastography (PROCEDURE).
Who is sponsoring clinical trial NCT04785534?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04785534 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver and Intrahepatic Bile Duct Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
RECRUITING · NA
-
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI